<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(1)</volume><submitter>Sun D</submitter><pubmed_abstract>The treatment of gastric cancer remains challenging, with immunotherapy serving as a critical component of the holistic approach to its treatment. The results of this study indicated that statins could decrease the serum levels of interleukin-enhancing binding factor 3 (ILF3) and programmed cell death ligand 1(PD-L1) in GC patients and improve their prognosis. Functional experiments demonstrated that simvastatin induced ferroptosis by inhibiting ILF3 in GC cells and enhanced the killing effect of activated CD8&lt;sup>+&lt;/sup> T cells on GC cells. The CUT&amp;Tag assay revealed that, mechanistically, simvastatin inhibited ILF3 expression by reducing the acetylation level at residue site H3K14 in ILF3. Next-generation sequencing and Kyoto Encyclopedia of Genes and Genomes analysis revealed that ILF3</pubmed_abstract><journal>Cell death &amp; disease</journal><pagination>208</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11947124</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Simvastatin inhibits PD-L1 via ILF3 to induce ferroptosis in gastric cancer cells.</pubmed_title><pmcid>PMC11947124</pmcid><pubmed_authors>Yang W</pubmed_authors><pubmed_authors>Wei M</pubmed_authors><pubmed_authors>Yan Z</pubmed_authors><pubmed_authors>Sun D</pubmed_authors><pubmed_authors>Cui X</pubmed_authors><pubmed_authors>Yu W</pubmed_authors><pubmed_authors>Zhang M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Simvastatin inhibits PD-L1 via ILF3 to induce ferroptosis in gastric cancer cells.</name><description>The treatment of gastric cancer remains challenging, with immunotherapy serving as a critical component of the holistic approach to its treatment. The results of this study indicated that statins could decrease the serum levels of interleukin-enhancing binding factor 3 (ILF3) and programmed cell death ligand 1(PD-L1) in GC patients and improve their prognosis. Functional experiments demonstrated that simvastatin induced ferroptosis by inhibiting ILF3 in GC cells and enhanced the killing effect of activated CD8&lt;sup>+&lt;/sup> T cells on GC cells. The CUT&amp;Tag assay revealed that, mechanistically, simvastatin inhibited ILF3 expression by reducing the acetylation level at residue site H3K14 in ILF3. Next-generation sequencing and Kyoto Encyclopedia of Genes and Genomes analysis revealed that ILF3</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2025-07-02T03:04:43.299Z</modification><creation>2025-07-02T03:04:43.299Z</creation></dates><accession>S-EPMC11947124</accession><cross_references><pubmed>40140647</pubmed><doi>10.1038/s41419-025-07562-8</doi></cross_references></HashMap>